COVID-19: an announcement from Gilead

An announcement from Jaime McCoy, General Manager and Paul Slade, Senior Medical Director of Gilead Sciences Australia and New Zealand on the impact of COVID-19.

As the impact of COVID-19 continues to grow, we want to assure you that our priority is protecting the safety and wellbeing of our staff and everyone we work with, including our valued colleagues like yourself.

We all face challenges now to help reduce the risk of spread of COVID-19. To ensure that we don’t add to this burden, we wanted to notify you that Gilead employees will not be visiting you in person for the time being, however rest assured we continue to be available by phone, email and video conference should you have any enquiries.

As a global pharmaceutical company with decades of antiviral expertise, we are in a unique position to be able to mobilise resources and research capacities to rapidly respond to the COVID-19 outbreak and advance potential treatments that may help in the global response to this public health emergency.

While we continue to accelerate our efforts in this area, we also want to assure you that we are already enacting continuity plans to ensure normal manufacture and distribution of existing treatments. Our team remains fully operational across the globe as we work remotely to ensure patients can receive uninterrupted supply.

At this point in time we ask that you continue to follow your regular prescribing or dispensing wherever possible, and rest assured we have contingencies in place for various scenarios.

We will provide additional updates as necessary and please don’t hesitate to reach out to your Gilead representative in the meantime if you have any questions.

Thank you again for your support, and stay well.

Jamie McCoy
General Manager
Gilead Sciences Australia New Zealand

Paul Slade
Senior Medical Director
Gilead Sciences Australia New Zealand

Now reading: COVID-19: an announcement from Gilead